Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.62 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.58 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.55 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.55 |
| ▸ | CCR3 | P51677 | 4/20 | 0.52 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | SMO | Q99835 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1036726 | 0.89 | DRD4 (0.59) | DRD4SIGMAR1LMNASMN1; SMN2CXCR4 | |
| SCHEMBL1033229 | 0.84 | DRD4 (0.64) | DRD4MCHR1SIGMAR1SLC6A12TMEM97 | |
| SCHEMBL1037205 | 0.83 | PRKAA2 (0.59) | MCHR1SIGMAR1SLC6A12TMEM97CCR3 | |
| SCHEMBL60695 | 0.83 | HDAC1 (0.58) | DRD4MCHR1SIGMAR1SLC6A12TMEM97 | |
| SCHEMBL62237 | 0.80 | DRD4 (0.76) | DRD4MCHR1SIGMAR1SLC6A12TMEM97 | |
| SCHEMBL1037177 | 0.78 | PRKAA2 (0.58) | DRD4SLC6A12PRKAA2DRD2SLC6A13 | |
| SCHEMBL16938670 | 0.77 | DRD4 (0.62) | DRD4MCHR1SIGMAR1SLC6A12TMEM97 | |
| SCHEMBL12227417 | 0.77 | PRKAA2 (0.54) | PRKAA2DRD2 | |
| SCHEMBL60786 | 0.75 | DRD4 (0.54) | DRD4MCHR1SIGMAR1SLC6A12TMEM97 | |
| SCHEMBL2386411 | 0.75 | DRD4 (0.66) | DRD4MCHR1SIGMAR1SLC6A12TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9255085-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-09 | — | — | US | claimed |
| US-20150232451-A1 | Carboxamide Compounds and Methods for Using the Same | MIDCAP FINANCIAL TRUST | 2015-08-20 | — | — | US | claimed |
| EP-2276761-B1 | CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | RIGEL PHARMACEUTICALS INC (US) | 2015-07-29 | — | — | EP | claimed |
| US-8314107-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | claimed |
| JP-2011527665-A | — | — | 2011-11-04 | — | — | JP | claimed |
| EP-2276761-A1 | CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Rigel Pharmaceuticals, Inc. (US) | 2011-01-26 | — | — | EP | claimed |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | claimed |
| WO-2009132136-A1 | CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | claimed |
| CN-112079769-A | Carboxamide compounds for the treatment of metabolic disorders | 里格尔药品股份有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-106928211-B | Carboxamide compounds for the treatment of metabolic disorders | 里格尔药品股份有限公司 | 2020-09-08 | — | — | CN | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9409884-B2 | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9353111-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2276761-A1 | CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Rigel Pharmaceuticals, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009132136-A1 | CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009132136-A1 | CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232451-A1 | Carboxamide Compounds and Methods for Using the Same | PC, AK2, PRKAA2 | DRD4 2543/4885MCHR1 2887/4885SIGMAR1 2015/4885 |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | PC, AK2, PRKAA2 | DRD4 2543/4885MCHR1 2887/4885SIGMAR1 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.